Prognia
Drug Database
🇪🇺EU · EMARefusedATC: L01DB01

Doxolipad(doxorubicin hydrochloride)

Breast Neoplasms;Ovarian Neoplasms

Marketing Authorisation Holder: TLC Biopharmaceuticals B.V.

INN: doxorubicin

Indication

Treatment of breast and ovarian cancer.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Doxolipad — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.